Key Points Amgen offers an attractive dividend and significant upside potential. Vertex Pharmaceuticals is a great biotech ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Veteran biopharma executive, Michael P. Cooke, PhD, joins Stratus to accelerate development of its pioneering Stratus Prime™ hematopoietic stem cell platformCAMBRIDGE, Mass., June 02, 2025 (GLOBE ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform.

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

Welcome to our live ASX coverage for Monday, June 2. We’re excited to be trialing this new format. Be sure to refresh ...